<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853331</url>
  </required_header>
  <id_info>
    <org_study_id>3475-426</org_study_id>
    <secondary_id>2016-000588-17</secondary_id>
    <secondary_id>163460</secondary_id>
    <secondary_id>MK-3475-426</secondary_id>
    <secondary_id>KEYNOTE-426</secondary_id>
    <nct_id>NCT02853331</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)</brief_title>
  <official_title>A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475)
      in combination with axitinib versus sunitinib monotherapy as a first-line treatment for
      participants with advanced/metastatic renal cell carcinoma (mRCC).

      The primary hypotheses of this study are:

        1. The combination therapy of pembrolizumab plus axitinib is superior to sunitinib
           monotherapy with respect to Progression-Free Survival (PFS) as assessed by blinded
           independent central imaging review per Response Evaluation Criteria in Solid Tumors
           version 1.1 (RECIST 1.1)

        2. The combination therapy of pembrolizumab plus axitinib is superior to sunitinib
           monotherapy with respect to Overall Survival (OS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 16, 2016</start_date>
  <completion_date type="Anticipated">January 27, 2022</completion_date>
  <primary_completion_date type="Actual">October 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The ORR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>DCR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions), Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), or Stable Disease (SD) per RECIST 1.1 for ≥6 months. The DCR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR, PR, or SD is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>DOR was defined as the time from first documented evidence of a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 until progressive disease (PD) or death due to any cause, whichever occurred first. PD was defined per RECIST 1.1 as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. The DOR for all participants who experienced a CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFS Rate) at Month 12 in All Participants</measure>
    <time_frame>Month 12</time_frame>
    <description>The PFS rate was determined in all participants at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 12 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFS Rate) at Month 18 in All Participants</measure>
    <time_frame>Month 18</time_frame>
    <description>The PFS rate was determined in all participants at Month 18. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 18 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFS Rate) at Month 24 in All Participants</measure>
    <time_frame>Month 24</time_frame>
    <description>The PFS rate was determined in all participants at Month 24. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at Month 12 in All Participants</measure>
    <time_frame>Month 12</time_frame>
    <description>The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 12 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at Month 18 in All Participants</measure>
    <time_frame>Month 18</time_frame>
    <description>The OS rate was determined for all participants at Month 18 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 18 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at Month 24 in All Participants</measure>
    <time_frame>Month 24</time_frame>
    <description>The OS rate was determined for all participants at Month 24 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) of the Functional Assessment of Cancer Therapy Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) Score</measure>
    <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
    <description>TTD was defined as time (in months) from the first dose of study treatment to the date of deterioration of FKSI-DRS Score. The FKSI-DRS was a questionnaire that asked the participant to rate 9 kidney cancer-related symptoms: lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or blood in the urine. Each item was scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration was defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration was the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). The time to true deterioration as measured in months is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares (LS) Mean Change From Baseline to Week 54 in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score</measure>
    <time_frame>Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days]) and Week 54</time_frame>
    <description>EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Baseline EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score</measure>
    <time_frame>Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days])</time_frame>
    <description>EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The mean baseline EORTC QLQ-C30 score is presented.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">861</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Axitinib Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Pembrolizumab+Axitinib Combination Therapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Pembrolizumab+Axitinib Combination Therapy</arm_group_label>
    <other_name>INLYTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Sunitinib Monotherapy</arm_group_label>
    <other_name>SUTENT®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has histologically confirmed diagnosis of RCC with clear cell component with or
             without sarcomatoid features.

          -  Has locally advanced/metastatic disease (i.e., newly diagnosed Stage IV RCC per
             American Joint Committee on Cancer) or has recurrent disease.

          -  Has measurable disease per RECIST 1.1 as assessed by the investigator/site
             radiologist.

          -  Has received no prior systemic therapy for advanced RCC.

          -  Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
             of a tumor lesion not previously irradiated.

          -  Has Karnofsky performance status (KPS) ≥ 70% as assessed within 10 days prior to
             randomization.

          -  If receiving bone resorptive therapy (including but not limited to bisphosphonate or
             RANK-L inhibitor) must have therapy initiated at least 2 weeks prior to randomization.

          -  Demonstrates adequate organ function.

          -  Female participants of childbearing potential must be willing to use an adequate
             method of contraception for the course of the study through 120 days after the last
             dose of study drug.

          -  Male participants of childbearing potential must agree to use an adequate method of
             contraception, starting with the first dose of study drug through 120 days after the
             last dose of study drug.

        Exclusion Criteria:

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to randomization.

          -  Has had major surgery within 4 weeks, received radiation therapy within 2 weeks prior
             to randomization, or has not recovered (i.e., ≤ Grade 1 or at baseline) from AEs due
             to prior treatment.

          -  Has had prior treatment with any anti-programmed cell death (anti-PD-1), or programmed
             cell death ligand 1 (PD-L1), or PD-L2 agent or an antibody targeting any other
             immune-regulatory receptors or mechanisms.

          -  Has received prior systemic anti-cancer therapy for RCC with vascular endothelial
             growth factor (VEGF)/VEGF receptors (VEGFR) or mechanistic target of rapamycin (mTOR)
             targeting agents.

          -  Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema,
             hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib.

          -  Has a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy
             exceeding physiologic corticosteroid dose or any other form of immunosuppressive
             therapy within 7 days prior to randomization, except in the case of central nervous
             system (CNS) metastases.

          -  Has an active autoimmune disease requiring systemic treatment with in the past 2 years
             OR a documented history of clinically severe autoimmune disease. Note: Participants
             with vitiligo, Sjøgren's syndrome, Type 1 diabetes, resolved childhood asthma/atopy,
             hypothyroidism or adrenal or pituitary insufficiency who are stable on hormone
             replacement, are not excluded.

          -  Has a known additional malignancy that has progressed or has required active treatment
             in the last 3 years. Note: Basal cell carcinoma of the skin, squamous cell carcinoma
             of the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer in
             situ are acceptable if they have undergone potentially curative therapy.

          -  Has known active CNS metastases and/or carcinomatous meningitis.

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of Human Immunodeficiency Virus (HIV).

          -  Has known active Hepatitis B or Hepatitis C infection.

          -  Has received a live virus vaccine within 30 days of randomization.

          -  Has a clinically significant gastrointestinal (GI) abnormality including:

          -  Malabsorption, total gastric resection

          -  Or any condition that might affect the absorption of orally taken medication

          -  Active GI bleeding, as evidenced by hematemesis, hematochezia or melena in the past 3
             months without evidence of resolution documented by endoscopy or colonoscopy

          -  Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease,
             ulcerative colitis or other GI condition associated with increased risk of perforation

          -  Has QT interval corrected for heart rate (QTc) ≥480 msec.

          -  Has a history of any of the following cardiovascular conditions within 12 months of
             randomization:

          -  Myocardial infarction

          -  Unstable angina pectoris

          -  Cardiac angioplasty or stenting

          -  Coronary/peripheral artery bypass graft

          -  Class III or IV congestive heart failure per New York Heart Association

          -  Cerebrovascular accident or transient ischemic attack

          -  Has a history of deep vein thrombosis or pulmonary embolism within 6 months of
             screening.

          -  Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg
             and/or diastolic blood pressure (DBP) ≥90 mm Hg.

          -  Has evidence of inadequate wound healing.

          -  Has active bleeding disorder or other history of significant bleeding episodes within
             30 days of randomization.

          -  Has hemoptysis within 6 weeks prior to randomization.

          -  Has current use (within 7 days of randomization) or anticipated need for treatment
             with drugs or foods that are known strong cytochrome P450 (CYP3A4/5) inhibitors.

          -  Has current use (within 7 days of randomization) or anticipated need for treatment
             with drugs that are known strong CYP3A4/5 inducers, including but not limited to
             carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort; or
             drugs that are known with proarrhythmic potential.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the study.

          -  Has had a prior solid organ transplant.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <results_first_submitted>October 18, 2019</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2019</results_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PDL2</keyword>
  <keyword>PD-L2</keyword>
  <keyword>VEGFR TKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02853331/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>These interim results are based on a database cutoff date of 24-Aug-2018, at which time 693 participants were ongoing in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab + Axitinib</title>
          <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Sunitinib</title>
          <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="429"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="429"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing in study</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
                <participants group_id="P2" count="325"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab + Axitinib</title>
          <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Sunitinib</title>
          <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="432"/>
            <count group_id="B2" value="429"/>
            <count group_id="B3" value="861"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="10.0"/>
                    <measurement group_id="B2" value="60.8" spread="10.2"/>
                    <measurement group_id="B3" value="61.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                    <measurement group_id="B2" value="387"/>
                    <measurement group_id="B3" value="764"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="341"/>
                    <measurement group_id="B3" value="684"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Group</title>
          <description>Participants were stratified by IMDC risk group using the following criteria: baseline Karnofsky Performance Status &lt;80%; interval between initial diagnosis of renal cell carcinoma to start of first-line systemic treatment for advanced disease &lt;1year; baseline hemoglobin &lt;lower limit of normal (LLN); baseline platelet count &gt;upper limit of normal (ULN); baseline corrected calcium1 &gt;ULN; and baseline neutrophil &gt;ULN. The category was determined by totaling the risk factors per participant and scored as favorable (no factors); intermediate (1 or 2 factors); and poor (≥3 factors).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Favorable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <description>Participants were stratified by geographic region using the following categories: North America; Western Europe; and Rest of the World.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of World</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
        <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
          <description>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 was calculated using the product-limit (Kaplan-Meier) method for censored data. The PFS for participants is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="12.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="11.0" lower_limit="8.7" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.00012</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>HR based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by IMDC risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">OS median, OS lower limit &amp; OS upper limit were not reached by the time of the data cutoff (24-Aug-2018).</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">OS median, OS lower limit &amp; OS upper limit were not reached by the time of the data cutoff (24-Aug-2018).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.00005</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>HR based on Cox regression model with Efron’s method of tie handling with treatment as a covariate stratified by IMDC risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
        <description>ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The ORR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR or PR is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
          <description>ORR was determined per RECIST 1.1 and was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The ORR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR or PR is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="54.5" upper_limit="63.9"/>
                    <measurement group_id="O2" value="35.7" lower_limit="31.1" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Miettinen &amp; Nurminen method</method>
            <method_desc>H0: difference in %=0 versus H1: difference in % &gt;0</method_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>23.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.2</ci_lower_limit>
            <ci_upper_limit>29.9</ci_upper_limit>
            <estimate_desc>Difference in percentages based on Miettinen &amp; Nurminen method stratified by IMDC risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
        <description>DCR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions), Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), or Stable Disease (SD) per RECIST 1.1 for ≥6 months. The DCR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR, PR, or SD is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all randomized participants who experienced a PR, CR or SD for ≥6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
          <description>DCR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions), Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), or Stable Disease (SD) per RECIST 1.1 for ≥6 months. The DCR was calculated using the Miettinen &amp; Nurminen method stratified by International Metastatic Renal Cell Carcinoma (RCC) Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World). The percentage of participants who experienced a CR, PR, or SD is presented.</description>
          <population>The analysis population consisted of all randomized participants who experienced a PR, CR or SD for ≥6 months.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="67.0" upper_limit="75.7"/>
                    <measurement group_id="O2" value="60.6" lower_limit="55.8" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
            <estimate_desc>Difference in percentages based on Miettinen &amp; Nurminen method stratified by IMDC risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of World).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
        <description>DOR was defined as the time from first documented evidence of a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 until progressive disease (PD) or death due to any cause, whichever occurred first. PD was defined per RECIST 1.1 as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. The DOR for all participants who experienced a CR or PR is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all randomized participants who experienced a CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Imaging Review</title>
          <description>DOR was defined as the time from first documented evidence of a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 until progressive disease (PD) or death due to any cause, whichever occurred first. PD was defined per RECIST 1.1 as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. The DOR for all participants who experienced a CR or PR is presented.</description>
          <population>The analysis population consisted of all randomized participants who experienced a CR or PR.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="1.4" upper_limit="NA">Median DOR not reached by the time of the data cutoff (24-Aug-2018). DOR upper limit not calculated due to no progressive disease by the time of last disease assessment.</measurement>
                    <measurement group_id="O2" value="15.2" lower_limit="1.1" upper_limit="NA">DOR upper limit not calculated due to no progressive disease by the time of last disease assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all participants who received ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE is presented.</description>
          <population>The analysis population consisted of all participants who received ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422"/>
                    <measurement group_id="O2" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>The analysis population consisted of all participants who received ≥1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.</description>
          <population>The analysis population consisted of all participants who received ≥1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Rate (PFS Rate) at Month 12 in All Participants</title>
        <description>The PFS rate was determined in all participants at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 12 is presented.</description>
        <time_frame>Month 12</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate (PFS Rate) at Month 12 in All Participants</title>
          <description>The PFS rate was determined in all participants at Month 12. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 12 is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="54.3" upper_limit="64.5"/>
                    <measurement group_id="O2" value="46.1" lower_limit="40.5" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Rate (PFS Rate) at Month 18 in All Participants</title>
        <description>The PFS rate was determined in all participants at Month 18. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 18 is presented.</description>
        <time_frame>Month 18</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate (PFS Rate) at Month 18 in All Participants</title>
          <description>The PFS rate was determined in all participants at Month 18. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment. The PFS rate at Month 18 is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="33.5" upper_limit="48.5"/>
                    <measurement group_id="O2" value="32.8" lower_limit="25.4" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival Rate (PFS Rate) at Month 24 in All Participants</title>
        <description>The PFS rate was determined in all participants at Month 24. PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The date of PD was approximated by the date of the first assessment at which PD was documented per RECIST 1.1 by Blinded Independent Central Review (BICR). Death was always considered as confirmed PD. Participants who did not experience PFS were censored at the last disease assessment.</description>
        <time_frame>Month 24</time_frame>
        <posting_date>01/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate at Month 12 in All Participants</title>
        <description>The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 12 is presented.</description>
        <time_frame>Month 12</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rate at Month 12 in All Participants</title>
          <description>The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 12 is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="86.4" upper_limit="92.4"/>
                    <measurement group_id="O2" value="78.3" lower_limit="73.8" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate at Month 18 in All Participants</title>
        <description>The OS rate was determined for all participants at Month 18 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 18 is presented.</description>
        <time_frame>Month 18</time_frame>
        <population>The analysis population consisted of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rate at Month 18 in All Participants</title>
          <description>The OS rate was determined for all participants at Month 18 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 18 is presented.</description>
          <population>The analysis population consisted of all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="77.2" upper_limit="86.3"/>
                    <measurement group_id="O2" value="72.1" lower_limit="66.3" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate at Month 24 in All Participants</title>
        <description>The OS rate was determined for all participants at Month 24 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment.</description>
        <time_frame>Month 24</time_frame>
        <posting_date>01/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to True Deterioration (TTD) of the Functional Assessment of Cancer Therapy Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) Score</title>
        <description>TTD was defined as time (in months) from the first dose of study treatment to the date of deterioration of FKSI-DRS Score. The FKSI-DRS was a questionnaire that asked the participant to rate 9 kidney cancer-related symptoms: lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or blood in the urine. Each item was scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration was defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration was the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). The time to true deterioration as measured in months is presented.</description>
        <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication and completed at least 1 questionnaire assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to True Deterioration (TTD) of the Functional Assessment of Cancer Therapy Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) Score</title>
          <description>TTD was defined as time (in months) from the first dose of study treatment to the date of deterioration of FKSI-DRS Score. The FKSI-DRS was a questionnaire that asked the participant to rate 9 kidney cancer-related symptoms: lack of energy, fatigue, weight loss, pain, bone pain, shortness of breath, cough, fever, or blood in the urine. Each item was scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration was defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration was the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). The time to true deterioration as measured in months is presented.</description>
          <population>All randomized participants who received at least 1 dose of study medication and completed at least 1 questionnaire assessment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="12.7" upper_limit="NA">TTD median not reached by the time of the data cutoff (24-Aug-2018). For TTD upper limit, no deterioration reached by the time of last disease assessment.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">TTD median not reached by the time of the data cutoff (24-Aug-2018). For TTD lower and upper limit, no deterioration reached by the time of last disease assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares (LS) Mean Change From Baseline to Week 54 in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score</title>
        <description>EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status.</description>
        <time_frame>Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days]) and Week 54</time_frame>
        <posting_date>01/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Baseline EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score</title>
        <description>EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The mean baseline EORTC QLQ-C30 score is presented.</description>
        <time_frame>Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days])</time_frame>
        <population>All participants with non-missing questionnaire assessments at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Baseline EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score</title>
          <description>EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The mean baseline EORTC QLQ-C30 score is presented.</description>
          <population>All participants with non-missing questionnaire assessments at baseline.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
                <count group_id="O2" value="410"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.90" spread="21.037"/>
                    <measurement group_id="O2" value="72.07" spread="20.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Least Squares (LS) Mean Change From Baseline to Week 30 in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score</title>
        <description>EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting [N/V], constipation, and pain) and a single item (financial difficulties). The last 2 questions represented the participant's assessment of overall health and quality of life on a 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100; with a high score indicating improved health status. Negative change from baseline values indicated deterioration in health status or functioning and positive changes indicated improvement. The LS Mean change from baseline to Week 30 is presented.</description>
        <time_frame>Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 days]) and Week 30</time_frame>
        <population>All participants who received at least 1 dose of study medication and had non-missing questionnaire assessments at baseline and Week 30.</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab + Axitinib</title>
            <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Change From Baseline to Week 30 in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score</title>
          <description>EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting [N/V], constipation, and pain) and a single item (financial difficulties). The last 2 questions represented the participant's assessment of overall health and quality of life on a 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100; with a high score indicating improved health status. Negative change from baseline values indicated deterioration in health status or functioning and positive changes indicated improvement. The LS Mean change from baseline to Week 30 is presented.</description>
          <population>All participants who received at least 1 dose of study medication and had non-missing questionnaire assessments at baseline and Week 30.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" lower_limit="-6.03" upper_limit="-2.07"/>
                    <measurement group_id="O2" value="-2.35" lower_limit="-4.44" upper_limit="-0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through Database Cutoff Date of 24-Aug-2018 (up to approximately 22 months)</time_frame>
      <desc>Population: All participants who received ≥1 dose of study treatment. Per protocol, progression of cancer under study was not considered an AE unless related to study drug. Therefore, MedDRA preferred terms &quot;Neoplasm progression&quot;, &quot;Malignant neoplasm progression&quot; &amp; &quot;Disease progression&quot; not related to study drug are excluded as AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab + Axitinib</title>
          <description>Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Sunitinib</title>
          <description>Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="429"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Adrenocorticotropic hormone deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Secondary adrenocortical insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="429"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatitis fulminant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Extrapulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pancreas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood electrolytes abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pachymeningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="429"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Epiglottic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="417" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="415" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="429"/>
                <counts group_id="E2" events="152" subjects_affected="97" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E2" events="79" subjects_affected="41" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E2" events="152" subjects_affected="82" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="429"/>
                <counts group_id="E2" events="164" subjects_affected="95" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="58" subjects_affected="53" subjects_at_risk="429"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="177" subjects_affected="152" subjects_at_risk="429"/>
                <counts group_id="E2" events="172" subjects_affected="133" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="64" subjects_affected="48" subjects_at_risk="429"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="107" subjects_affected="89" subjects_at_risk="429"/>
                <counts group_id="E2" events="70" subjects_affected="62" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="496" subjects_affected="231" subjects_at_risk="429"/>
                <counts group_id="E2" events="380" subjects_affected="191" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="429"/>
                <counts group_id="E2" events="73" subjects_affected="62" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="429"/>
                <counts group_id="E2" events="60" subjects_affected="48" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="174" subjects_affected="119" subjects_at_risk="429"/>
                <counts group_id="E2" events="205" subjects_affected="134" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="86" subjects_affected="67" subjects_at_risk="429"/>
                <counts group_id="E2" events="110" subjects_affected="88" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="97" subjects_affected="64" subjects_at_risk="429"/>
                <counts group_id="E2" events="125" subjects_affected="78" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="62" subjects_at_risk="429"/>
                <counts group_id="E2" events="77" subjects_affected="60" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="208" subjects_affected="165" subjects_at_risk="429"/>
                <counts group_id="E2" events="211" subjects_affected="158" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="77" subjects_affected="56" subjects_at_risk="429"/>
                <counts group_id="E2" events="143" subjects_affected="92" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="429"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="53" subjects_at_risk="429"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="429"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="429"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="54" subjects_affected="37" subjects_at_risk="429"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="158" subjects_affected="110" subjects_at_risk="429"/>
                <counts group_id="E2" events="81" subjects_affected="64" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="163" subjects_affected="108" subjects_at_risk="429"/>
                <counts group_id="E2" events="95" subjects_affected="69" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="429"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="28" subjects_at_risk="429"/>
                <counts group_id="E2" events="39" subjects_affected="24" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="79" subjects_affected="48" subjects_at_risk="429"/>
                <counts group_id="E2" events="72" subjects_affected="51" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="429"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="429"/>
                <counts group_id="E2" events="109" subjects_affected="50" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="429"/>
                <counts group_id="E2" events="148" subjects_affected="76" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="86" subjects_affected="76" subjects_at_risk="429"/>
                <counts group_id="E2" events="54" subjects_affected="47" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" events="97" subjects_affected="43" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="173" subjects_affected="126" subjects_at_risk="429"/>
                <counts group_id="E2" events="156" subjects_affected="125" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="31" subjects_at_risk="429"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="30" subjects_at_risk="429"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="429"/>
                <counts group_id="E2" events="57" subjects_affected="36" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="78" subjects_at_risk="429"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="64" subjects_affected="55" subjects_at_risk="429"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="429"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="69" subjects_affected="51" subjects_at_risk="429"/>
                <counts group_id="E2" events="48" subjects_affected="42" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="429"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="429"/>
                <counts group_id="E2" events="185" subjects_affected="131" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="91" subjects_affected="67" subjects_at_risk="429"/>
                <counts group_id="E2" events="87" subjects_affected="68" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="429"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="429"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="104" subjects_affected="74" subjects_at_risk="429"/>
                <counts group_id="E2" events="77" subjects_affected="47" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="108" subjects_affected="91" subjects_at_risk="429"/>
                <counts group_id="E2" events="66" subjects_affected="58" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="126" subjects_affected="109" subjects_at_risk="429"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="80" subjects_affected="69" subjects_at_risk="429"/>
                <counts group_id="E2" events="49" subjects_affected="44" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="429"/>
                <counts group_id="E2" events="45" subjects_affected="40" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="429"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="429"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="140" subjects_affected="118" subjects_at_risk="429"/>
                <counts group_id="E2" events="235" subjects_affected="169" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="78" subjects_affected="65" subjects_at_risk="429"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="84" subjects_affected="61" subjects_at_risk="429"/>
                <counts group_id="E2" events="60" subjects_affected="47" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="317" subjects_affected="189" subjects_at_risk="429"/>
                <counts group_id="E2" events="278" subjects_affected="192" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

